NCT04840888

A Study of LY3484356 in Healthy Female Participants

Evaluation of the Effect of Food, Omeprazole, Itraconazole, and Carbamazepine on the Pharmacokinetics of LY3484356 in Healthy Females of Non-Child-Bearing Potential

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3484356	Administered orally.
DRUG	Omeprazole	Administered orally.
DRUG	Itraconazole	Administered orally.
DRUG	Carbamazepine	Administered orally.
DRUG	Midazolam	Administered orally.

Timeline

• Start date: 2021-04-26
• Primary completion: 2022-04-12
• Completion: 2022-04-12
• First posted: 2021-04-12
• Last updated: 2025-12-11
• Results posted: 2025-12-11

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study